OrbiMed Asia is a private equity general partner firm with offices in China and India.
InventisBio, a China-based biotech company, raised $19m in Series B from OrbiMed Asia Partners and Lilly Asia Ventures.
CBT Pharmaceuticals, a CA-based life sciences company, has closed a $9.75m Series A financing led by OrbiMed Asia.
Zai Lab, a China-based biopharmaceutical company, secured over $100m in Series B financing from OrbiMed, Sequoia Capital and others.
Read more news concerning OrbiMed Asia
A sampling of OrbiMed Asia portfolio companies:
View all of the investments in their portfolio
This firm also pursues other investment strategies:
Registration is fast, free and easy
Already a member?